Molecular recognition and regulation of human angiotensin-I converting enzyme (ACE) activity by natural inhibitory peptides

Scientific Reports

Volumn 2, Issue , 2012, Pages

  Masuyer, Geoffrey ^a   Schwager, Sylva L U ^b   Sturrock, Edward D ^b   Isaac, R Elwyn ^c   Acharya, K Ravi ^a  

^a University of Bath   (United Kingdom)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACE PROTEIN, HUMAN; ANGIOTENSIN II; BRADYKININ POTENTIATING FACTORS; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; OLIGOPEPTIDE;

ARTICLE; CHEMISTRY; HUMAN; METABOLISM; PROTEIN TERTIARY STRUCTURE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; X RAY CRYSTALLOGRAPHY;

ANGIOTENSIN II; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CRYSTALLOGRAPHY, X-RAY; HUMANS; OLIGOPEPTIDES; PEPTIDYL-DIPEPTIDASE A; PROTEIN STRUCTURE, TERTIARY; RENIN-ANGIOTENSIN SYSTEM;

EID: 84868271035     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep00717     Document Type: Article

References (41)

1. Bader, M. Tissue renin-angiotensin-aldosterone systems: Targets for pharmacological therapy. Annu. Rev. Pharmacol. Toxicol. 50, 439-465 (2010).
2. Kumar, R., Singh, V. P. & Baker, K. M. The intracellular renin-angiotensin system: A new paradigm. Trends Endocrinol. Metab. 18, 208-214 (2007). (Pubitemid 46962301)
3. Corvol, P., Eyries, M. & Soubrier, F. in Handbook of Proteolytic Enzymes edited byA. J. Barrett, N. D. Rawlings and J. F. Woessner (Elsevier Academic Press, Amsterdam, 2004), Vol. 1, pp. 332-346.
4. Soffer, R. L. Angiotensin-converting enzyme and the regulation of vasoactive peptides. Annu. Rev. Biochem. 45, 73-94. (1976).
5. Paul, M., Poyan Mehr, A. & Kreutz, R. Physiology of local renin-angiotensin systems. Physiol. Rev. 86, 747-803 (2006). (Pubitemid 44033382)
6. Navar, L. G., Kobori, H., Prieto, M. C. & Gonzalez-Villalobos, R. A. Intratubular renin-angiotensin system in hypertension. Hypertension 57, 355-362 (2011).
7. Abadir, P. M. et al. Identification and characterization of a functional mitochondrial angiotensin system. Proc. Natl. Acad. Sci. USA 108, 14849-14854 (2011).
8. Acharya, K. R., Sturrock, E. D., Riordan, J. F. & Ehlers, M. R. ACE revisited: A new target for structure-based drug design. Nat. Rev. Drug Discov. 2, 891-902 (2003). (Pubitemid 37407795)
9. Watermeyer, J. M., Kroger, W.L., Sturrock, E. D. & Ehlers, M. R. W. Angiotensin-converting enzyme-New insights into structure, biological significance and prospects for domain-selective inhibitors. Current Enzyme Inhibition 5, 134-147 (2009).
10. Hubert, C., Houot, A. M., Corvol, P. & Soubrier, F. Structure of the angiotensin I-converting enzyme gene-Two alternate promoters correspond to evolutionary steps of a duplicated gene. J. Biol. Chem. 266, 15377-15383 (1991). (Pubitemid 21907658)
11. Fuchs, S. et al. Angiotensin-converting enzyme C-terminal catalytic domain is the main site of angiotensin I cleavage in vivo. Hypertension 51, 267-274 (2008). (Pubitemid 351159938)
12. van Esch, J. H. et al. Selective angiotensin-converting enzyme C-domain inhibition is sufficient to prevent angiotensin I-induced vasoconstriction. Hypertension 45, 120-125 (2005). (Pubitemid 40066425)
13. Rousseau, A. et al. The hemoregulatory peptide N-acetyl-Ser-Asp-Lys-Pro is a natural and specific substrate of the N-terminal active site of human angiotensin-converting enzyme. J. Biol. Chem. 270, 3656-3661 (1995).
14. Todd, P. A. & Heel, R. C., Enalapril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure. Drugs 31, 198-248 (1986). (Pubitemid 16184167)
15. Israili, Z. H. & Hall, W. D. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology. Ann Intern Med 117, 234-242 (1992).
16. Burnakis, T. G. & Mioduch, H. J.Combined therapy with captopril and potassium supplementation. A potential for hyperkalemia. Arch Intern Med 144, 2371-2372 (1984). (Pubitemid 15214235)
17. Natesh, R., Schwager, S. L., Sturrock, E. D. & Acharya, K. R. Crystal structure of the human angiotensin-converting enzyme-lisinopril complex. Nature 421, 551-554 (2003). (Pubitemid 36168450)
18. Corradi, H. R. et al. The structure of testis angiotensin-converting enzyme in complex with the C-domain-specific inhibitor RXPA380. Biochemistry 46, 5473-5478 (2007). (Pubitemid 46717270)
19. Anthony, C. S. et al. The N domain of human angiotensin-I converting enzyme: the role of N-glycosylation and the crystal structure in complex with an N-domain specific phosphinic inhibitor RXP407. J. Biol. Chem. 285, 35685-35693 (2010).
20. Erdos, E. G. The ACE and I: how ACE inhibitors came to be. FASEB J 20, 1034-1038 (2006). (Pubitemid 44943898)
21. Cotton, J. et al. Selective inhibition of the C-domain of angiotensin I converting enzyme by bradykinin potentiating peptides. Biochemistry 41, 6065-6071 (2002). (Pubitemid 34498912)
22. Cheung, H. S. & Cushman, D. W. Inhibition of homogeneous angiotensin-converting enzyme of rabbit lung by synthetic venom peptides of Bothrops jararaca. Biochim Biophys Acta 293, 451-463 (1973).
23. Cushman, D. W. et al. Inhibition of angiotensin-coverting enzyme by analogs of peptides from Bothrops jararaca venom. Experientia 29, 1032-1035 (1973).
24. Rawlings, N. D., Morton, F. R., Kok, C. Y., Kong, J. & Barrett, A. J. (2008) MEROPS: the peptidase database.Nucleic Acids Res. 36 Database issue, D320-325. (Pubitemid 351149743)
25. Jaspard, E., Wei, L. & Alhenc-Gelas, F. Differences in the properties and enzymatic specificities of the two active sites of angiotensin I-converting enzyme (kininase II). Studies with bradykinin and other natural peptides. J. Biol. Chem. 268, 9496-9503 (1993). (Pubitemid 23146003)
26. Georgiadis, D. et al. Structural determinants of RXPA380, a potent and highly selective inhibitor of the angiotensin-converting enzyme C-domain. Biochemistry 43, 8048-8054 (2004). (Pubitemid 38808259)
27. Kroger, W. L. et al. Investigating the domain specificity of phosphinic inhibitors RXPA380 and RXP407 in angiotensin-converting enzyme. Biochemistry 48, 8405-8412 (2009).
28. Tsai, B-S. & Peach, M. J. Angiotensin homologs and analogs as inhibitors of rabbit pulmonary angiotensin-converting enzyme (1977). J Biol Chem 252, 4674-4681 (1977). (Pubitemid 8155991)
29. Campbell, D. J. et al. Effect of reduced angiotensin-converting enzyme gene expression and angiotensin-converting enzyme inhibition on angiotensin and bradykinin peptide levels in mice.Hypertension. 43, 854-859 (2004). (Pubitemid 38405600)
30. Rice, G. I. et al. Evaluation of angiotensin-converting enzyme (ACE), its homologue ACE2 and neprilysin in angiotensin peptide metabolism. Biochem. J. 383, 45-51 (2004). (Pubitemid 39389449)
31. Gordon, K. et al. Deglycosylation, processing and crystallization of human testis angiotensin-converting enzyme. Biochem. J. 371, 437-442 (2003). (Pubitemid 36547627)
32. Lamango, N. S. & Isaac, R. E. Identification and properties of a peptidyl dipeptidase in the housefly, Musca domestica, that resembles mammalian angiotensin-converting enzyme. Biochem. J. 299, 651-657 (1994). (Pubitemid 24138530)
33. Leslie, A. G. W. & Powell, H. R. Processing diffraction data with Mosflm. Evolving Methods for Macromolecular Crystallography 245, 41-51 (2007).
34. CCP4, The CCP4 suite: programs for protein crystallography. Acta Crystallogr D Biol Crystallogr 50, 760-763 (1994).
35. McCoy, A. J. et al. Phaser crystallographic software. J. Appl. Crystallogr. 40, 658-674 (2007). (Pubitemid 47080256)
36. Murshudov, G. N., Vagin, A. A. & Dodson, E. J. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr. D Biol. Crystallogr. 53, 240-255 (1997). (Pubitemid 27235885)
37. Brünger, A. T. Free R-value: A novel statistical quantity for assessing the accuracy of crystal structures. Nature 355, 472-475 (1992).
38. Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 60, 2126-2132 (2004). (Pubitemid 41742764)
39. Davis, I. W. et al. MolProbity: All-atom contacts and structure validation for proteins and nucleic acids. Nucleic Acids Res. 35 (issue) W375-383 (2007).
40. McDonald, I. K. & Thornton, J. M. Satisfying hydrogen bonding potential in proteins. J. Mol. Biol. 238, 777-793 (1994). (Pubitemid 24168633)
41. Marc, Y. & Llorens-Cortes, C. The role of the brain renin-angiotensin system in hypertension: Implications for new treatment. Prog. Neurobiol. 95, 89-103 (2011).